Disruptor of Lipid Enveloped Viruses

Treatment for Infectious Diseases / New Drug Delivery Platforms

  • Business
  • Disruptor of Lipid Enveloped Viruses

Disruptor of Lipid Enveloped Viruses

LUCA AICell has developed a novel drug candidate, peptides that targets and disrupts specific lipid membranes. This drug candidate is designed to attack lipid membranes surrounding harmful viruses in humans while preserving the integrity of human cell membranes. Extensive research has confirmed its efficacy against a wide range of viruses. LUCA AICell is currently focused on developing therapeutic applications based on this drug candidate.

  • Zika

  • Dengue Fever

  • Yellow Fever

  • Japanese Encephalitis

  • Chikungunya

  • Covid-19

  • Ebola

  • Marburg Fever

  • Rift Valley Fever

Infectious Diseases Drug Development Platform

Professor Nam-Joon Cho’s research team has been selected for the AViDD (Antiviral Drug Discovery and Development) Award funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) in the United States. This prestigious award provides funding support for their research, enabling them to progress to early-stage clinical trials. This recognition and financial support from the NIAID will significantly contribute to the advancement of LUCA AICell’s research and development efforts towards the potential development of effective antiviral therapies.

LUCA AICell is currently preparing for US FDA IND filing. As a broadspectrum virus treatment, it is possible to proceed rapidly from the 2nd stage of clinical trials for the development of new drugs for other viruses after obtaining new drug approval for one virus as a target.

Discovery of a Candidate

– Completed both in vivo and
in vitro studies for total
13 viruses including mutations

Preclinical Trials

– Covid-19 Zika, Dengue,
JEV, Rabies Virus

– Expected ’24 3Q

Clinical Trials

– NIAID supports studies
until clinical trial phase I

– Considering License-out
depending on the decision


– Selecting a partner